Introduction
Diuretics are an important therapeutic tool for managing heart failure (HF) patients. In particular, loop diuretics are a mainstream therapy that act by reducing fluids in patients with acute HF by inhibiting sodium reabsorption in the loop of Henle. By increasing the distal tubular delivery of sodium, loop diuretics activate the renin-angiotensin system, which causes vasoconstriction of the afferent arteriole and a reduction in renal blood flow. Loop diuretics also activate the sympathetic nervous system, resulting in poor outcomes (1) (2) (3) . Moreover, the use of loop diuretics can lead to serum potassium depletion, which can promote arrhythmias (4, 5) . Thus, loop diuretics are associated with poor outcomes that are broadly predictive of death and morbidity (6) .
Tolvaptan is a selective vasopressin V 2 receptor antagonist that disturbs the movement of aquaporin 2 to the luminal side of cortical collecting duct cells by activating cyclic adenosine monophosphate (cAMP). In addition, tolvaptan inhibits the reabsorption of water and produces water diuresis through a relatively recently identified mechanism of action (7, 8) .
Tolvaptan is an alternative to the use of loop diuretics that is expected to slow the progression of renal failure and improve the prognosis of HF patients. Specifically, tolvaptan exerts a protective effect on the kidney by initiating a diuretic effect without activating the renin-angiotensin system (1,2). Additionally, it has been shown that renal blood flow and the glomerular filtration rate (GFR) are not reduced by tolvaptan (9) . Hence, it has been suggested that tolvaptan administration reduces the risk of a decline in renal function in patients with acute HF syndrome (AHFS) (10) . Tolvaptan has been shown to be quick-acting when used to treat HF and was used in ACTIVE (11) and EVEREST (a test of the efficacy of vasopressin antagonism in HF outcomes study) (12, 13) studies. However, the primary mechanisms underlying the effects of tolvaptan on renal function have not been determined, and few reports have evaluated its efficacy when administered chronically. In the EVEREST, there was no significant improvement in two primary endpoints of all-cause mortality or in the rate of cardiovascular death or hospitalization for HF (14) .
However, the results of post-marketing surveillance in Japan demonstrated that 30% of patients with HF were also administered tolvaptan for greater than 2 weeks (15) . In clinical practice, some patients require chronic administration of tolvaptan. In this study, we investigated the effects of long-term administration of tolvaptan in patients with HF and chronic kidney disease (CKD).
Materials and Methods

Study population
This report is a retrospective observational study with no planned protocol. Thirty-one ADHF patients who were administered tolvaptan for 6 months or more from January 2013 to December 2016 were consecutively enrolled in the study. Twenty-seven HF patients with CKD and a past history of admission for HF from January 2013 to December 2016 were also consecutively enrolled. We compared the 31 patients with ADHF (TLV group) to the 27 patients with ADHF and CKD (conventional group).
Data collection
All data were collected retrospectively. Data from laboratory tests included serum creatinine (Cre) levels, serum concentrations of sodium, serum concentrations of potassium, and brain-type natriuretic peptide (BNP) levels. Tests were conducted at admission for ADHF (baseline), at discharge from ADHF and after a 6-months follow-up period. The estimate glomerular filtration rate (eGFR) was calculated using equation coefficients obtained from the modification of diet in renal disease (MDRD) study, which was performed in a Japanese population (16) . CKD was defined as a syndrome consisting of a low eGFR (< 60 mL min -1 •1.73 m -2 for longer than 3 months (17) . Based on the results of a previous study, we considered 20 mg furosemide to be equivalent to approximately 30 mg azosemide (18).
Outcomes
We evaluated renal function, dose changes in orally administered diuretics, New York Heart Association (NYHA) classification, ejection fraction (EF) and BNP before and at 6 months after discharge from ADHF.
Statistical analysis
All data were statistically analyzed using a standard statistical software package (StatMate IV ATMS Co., Ltd., Tokyo, Japan). All numerical data are expressed as the mean ± standard deviation. Unpaired Student's t-test or the Mann-Whitney U test was used to compare two groups. Categorical variables are expressed as a number (percent) and were compared by the chi-square or Fisher exact test. One-way analysis of variance (ANOVA) was used to detect significant factors among three or more groups. A p-value < 0.05 was considered statistically significant. Table 1 shows the baseline clinical characteristics of the conventional and TLV groups. These data were collected at hospital admission for ADHF. There were no significant differences in age, medications, Cre, eGFR and echocardiographic data between the two groups. eGFR at baseline was equivalent in both groups. All patients had a previous history of HF and CKD.
Results
Patients characteristics
The treatments administered during the acute phase are shown in Table 2 . There were no significant differences in the daily dose of furosemide between the conventional and TLV groups. Similarly, there were no significant differences in the inotropic agents used between the two treatment groups.
No side effects were observed, and no patients discontinued tolvaptan in the TLV group. The treatments administered during the chronic phase are shown in Table 3 . Concomitant medications included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, calcium blockers, loop diuretics, spironolactone, thiazide diuretics, and inotropic agents and were not significantly different between the conventional and TLV groups.
Changes in renal function
The changes in renal function observed during the study are shown in Table 4 . At the time of hospital discharge, eGFR and Cre had not significantly worsened since admission in either group. However, eGFR had significantly declined in the conventional group at 6 months after discharge (p = 0.001). A comparison of the changes observed in eGFR between discharge and 6 months follow-up in the conventional and TLV groups is shown in Figure 1 . In the TLV group, eGFR remained approximately the same (-1.1 ± 8.3), whereas in the such as angiotensin-converting enzyme inhibitors and, beta-blockers, between admission and 6-months after discharge in either group (Table 3) .
Changes in clinical data
The observed changes in clinical data are shown in Table 4 . NYHA classification improved between baseline and discharge in both groups. There were conventional group, it had declined at discharge (-7.4 ± 10.4).
Changes in medication dose
The dose of loop diuretics was higher (+17.8 ± 12.4) at 6 months after discharge in the TLV group than in the conventional group (p = 0.02) ( Table 4 ). There were no significant differences in cardio-protective medications, BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DL, dyslipidemia; CKD, chronic kidney disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; HF, heart failure; SBP, systolic blood pressure; DBP, diastolic blood pressure; Pulse P, pulse pressure; HR, heart rate; CS, clinical scenario; NYHA, New York Heart Association; BNP, brain natriuretic peptide; LVDd, left ventricular enddiastolic diameter; LVDs, left ventricular end-systolic diameter; EF, ejection fraction; MR, mitral regurgitation; HFpEF, heart failure with preserved ejection fraction; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensinII receptor blocker; CCB, calcium channel blocker; AAD, antiarrhythmic drugs. 
Table 4. Changes in clinical data
Conventional group eGFR (mL/min/1. 8.7 ± 5.0 68.1 ± 42.0* 24/6/1/0 51.8 ± 17.9 530 ± 500 no significant differences between the two groups in the changes in clinical data that occurred between discharge and 6 months later. There were no significant differences in EF between baseline and after 6 months of follow-up. BNP was improved in both groups between baseline and discharge. There were no significant differences in the changes that occurred from discharge to 6 months later between the groups. The observed clinical outcomes are shown in Table  5 . The frequency of hospitalization for HF was not significantly different between the groups.
Discussion
This study investigated the clinical effect of long-term administration of tolvaptan in HF patients with CKD. All patients in this study were dependent on high doses of diuretics for long-term periods of time. Although dose of loop diuretics was increased at 6 months follow-up, renal function did not worsen in TLV group.
Several studies have shown that renal function is an important factor when considering a prognosis for HF (19, 20) . Consequently, preserving renal function is a primary objective in patients with HF. The protective effects exerted by tolvaptan on renal function are likely attributable to several mechanisms. Specifically, Costello-Boerrigter et al. reported that renal blood flow and GFR were not reduced by tolvaptan (21) . In addition, the diuretic effects of tolvaptan may prevent the deterioration of eGFR by ameliorating congestive kidney failure without activating the reninangiotensin system (22) (23) (24) . In this study, the dose of furosemide was higher in the TLV group. Tolvaptan may therefore exert its renal-protecting effect even in patients administered high doses of furosemide. Renal congestion leads to increased renal interstitial pressure, which affects the entire capillary bed and tubules and can potentially induce local hypoxia. Tubular compression raises luminal pressure, further attenuating the transglomerular pressure gradient, and lowering the GFR (25) . Tolvaptan is thought to improve renal congestion without promoting renal failure because it affects water diuresis from interstitial tissue. Unfortunately, there is no direct method to assess renal congestion, and causal relationships between chronically administered of tolvaptan and improvements in renal congestion were therefore not investigated in this study.
As no side effect and electrolyte imbalance were observed after chronic administration of tolvaptan, chronic administration of tolvaptan could be a safe treatment for HF patients with CKD.
Several studies have reported that long-term administration of tolvaptan reduced the frequency of admission for HF (26, 27) . However, the frequency of hospitalization for HF was not significantly different between the groups in this study. The dose of loop diuretics is considered a predictor of hospitalization for HF and was significantly higher in the TLV group, which may have affected this outcome (28, 29) . All patients had previously been hospitalized for ADHF and CKD. Previous studies have shown that a past history of hospitalization for HF is an independent risk factor for cardiovascular death in HF patients (30) . Additionally, CKD is reportedly an independent risk factor for adverse outcomes in HF patients (19) . As mentioned above, the patients in this study were considered to have poor prognoses. Moreover, indications for administration of tolvaptan were left to the discretion of the physician. The TLV group might have had a more severe background. This outcome should be confirmed in a further prospective large-scale study.
Our study has several limitations. 1) This was a retrospective observational study, and a small number of patients in a single center were included. 2) Patient characteristics were not identified.
3) The indications for long-term administration of tolvaptan were left to the discretion of the physician.
In conclusion, the results of our study suggest that chronic administration of tolvaptan may prevent increased renal dysfunction in HF patients with CKD and prior history of HF. Tolvaptan could be a safe and useful diuretic for HF patients with CKD. This conclusion should be confirmed in a future prospective study. 
